One of the hot topics in the prostate cancer community is the value of detecting AR-V7 tumor cells circulating in the blood. AR-V7 tumor cells in the blood predicts response or failure of treatment with enzalutamide (Xtandi) or abiraterone (Zytiga). A recent study found that men who have AR-V7 circulating tumor cells in their blood will not [...]
In the near future we should be seeing more non-invasive methods to evaluate if a man is responding to their drugs. One such example is the blood bio-marker available only at Johns Hopkins, the Androgen Receptor Variant 7 (AR-V7). Evaluating the presence of the antibody AR-V7 in the blood strongly indicates whether or not both [...]
At the current AUA Annual Meeting going on in New Orleans, there was a presentation given by Haitao Zhang and colleagues. They described their work developing a novel blood-based assay (test) for detecting androgen receptor (AR) splice variants in men with advanced prostate cancer. Their work relies on the premise that AR-V7 expression underlies resistance [...]
